• 8312 Citations
  • 37 h-Index
1987 …2024

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Outputs

Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment

Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators, 1 Sep 2018, In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.

Research output: Contribution to journalArticle

Open Access
File
23 Citations (Scopus)
9 Downloads (Pure)

Accelerated BEP for advanced germ cell tumors: an Australian multicenter phase I/II trial.

Grimison, P. S., Thomson, D. B., Stockler, M. R., Chatfield, M. D., Friedlander, M., Gebski, V., Boland, A. L., Houghton, B. B., Gurney, H., Rosenthal, M., Singhal, N., Kichenadasse, G., Wong, S. S., Lewis, C. R., Vasey, P. A., Toner, G. C. & Australian New Zealand Urogenital, 20 May 2011, In : Journal of Clinical Oncology. 29, 15 supplement, p. 4561-4561 1 p.

Research output: Contribution to journalMeeting abstract

49 Citations (Scopus)

Accelerated BEP for metastatic germ cell tumors: combined analysis of Australian and UK phase I/II trials

Grimison, P. S., Chatfield, M. D., Mazhar, D., Toner, G. C., Chester, J. D., Stockler, M. R., Stark, D. P., Thomson, D. B., Shamash, J., Friedlander, M., White, J., Gebski, V., Wason, J., Boland, A. L., Rimmer, Y. L., McDonald, A., Gurney, H., Rosenthal, M., Singhal, N., Williams, M. V. & 2 others, Australian New Zealand Urogenital & West Anglia Cancer Research Network, 20 May 2012, In : Journal of Clinical Oncology. 30, 15 supplement, p. 4531-4531 1 p.

Research output: Contribution to journalMeeting abstract

Accelerated BEP for metastatic germ cell tumours: A multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Grimison, P. S., Stockler, M. R., Chatfield, M., Thomson, D. B., Gebski, V., Friedlander, M., Boland, A. L., Houghton, B., Gurney, H., Rosenthal, M., Singhal, N., Kichenadasse, G., Wong, S. S., Lewis, C. R., Vasey, P. A. & Toner, G. C., 2014, In : Annals of Oncology. 25, 1, p. 143-148 6 p., mdt369.

Research output: Contribution to journalArticle

20 Citations (Scopus)

A cost-utility approach to the use of 5-fluorouracil and levamisole ad adjuvant chemotherapy for Dukes' C colonic carcinoma

Smith, R. D., Hall, J., Gurney, H. & Harnett, P. R., 1993, In : Medical Journal of Australia. 158, 5, p. 319-320 2 p.

Research output: Contribution to journalArticle

35 Citations (Scopus)

A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma [5]

De Souza, P., Smith, R. D., Hall, J., Gurney, H. & Harnett, P. R., 1993, In : Medical Journal of Australia. 158, 12, p. 866 1 p.

Research output: Contribution to journalLetter

A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for dukes c-colonic carcinoma - Reply

Smith, RD., Hall, J., Gurney, H. & Harnett, PR., 21 Jun 1993, In : Medical Journal of Australia. 158, 12, p. 866-866 1 p.

Research output: Contribution to journalLetter

A Distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer

PRIMe Consortium, 15 Nov 2017, In : International Journal of Cancer. 141, 10, p. 2112-2120 9 p.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

Spry, N. A., Kristjanson, L., Hooton, B., Hayden, L., Neerhut, G., Gurney, H., Corica, T., Korbel, E., Weinstein, S. & McCaul, K., May 2006, In : European Journal of Cancer. 42, 8, p. 1083-1092 10 p.

Research output: Contribution to journalArticle

91 Citations (Scopus)

Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: Possible evidence of graft-versus-tumour effect

Goodwin, A., Gurney, H. & Gottlieb, D., Feb 2007, In : Internal Medicine Journal. 37, 2, p. 127-129 3 p.

Research output: Contribution to journalReview article

2 Citations (Scopus)

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer

Pezaro, C., Rosenthal, M. A., Gurney, H., Davis, I. D., Underhill, C., Boyer, M. J., Kotasek, D., Solomon, B. & Toner, G. C., Aug 2009, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 32, 4, p. 338-341 4 p.

Research output: Contribution to journalArticle

39 Citations (Scopus)

A phase-I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving intensive chemotherapy for small-cell lung-cancer

Anderson, H., Gurney, H., Radford, J., Steward, WP., Kamthan, A., Chang, J. & Thatcher, N., Sep 1990, In : British Journal of Cancer. 62, 3, p. 528-528 1 p.

Research output: Contribution to journalMeeting abstract

200 Citations (Scopus)

A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer

Lind, M. J., Gomm, S., Simmonds, A. P., Ashcroft, L., Kamthan, A., Gurney, H. & Thatcher, N., Mar 1991, In : Cancer Chemotherapy and Pharmacology. 28, 2, p. 142-144 3 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

A phase-II study of ifosfamide and alpha-2 interferon (intron-A) in advanced non-small cell lung-cancer

Lind, MJ., Thatcher, N., Gurney, H. & Kamthan, A., Sep 1990, In : British Journal of Cancer. 62, 3, p. 502-502 1 p.

Research output: Contribution to journalMeeting abstract

A phase II trial of paclitaxel and epirubicin in advanced breast cancer

Rischin, D., Smith, J., Millward, M., Lewis, C., Boyer, M., Richardson, G., Toner, G., Gurney, H. & McKendrick, J., 2000, In : British Journal of Cancer. 83, 4, p. 438-442 5 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy

Lam, T., McLean, M., Hayden, A., Poljak, A., Cheema, B., Gurney, H., Stone, G., Bahl, N., Reddy, N., Shahidipour, H. & Birzniece, V., 1 May 2019, In : Endocrine Connections. 8, 5, p. 605-615 11 p.

Research output: Contribution to journalArticle

Open Access
File
2 Downloads (Pure)

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Sternberg, C. N., Saad, F., Graff, J. N., Peer, A., Vaishampayan, U. N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R. J., Davis, I. D., Wu, B., Trandafir, L., Wagner, V. J. & Hussain, M., 1 Feb 2020, In : Annals of Oncology. 31, 2, p. 257-265 9 p.

Research output: Contribution to journalArticle

Open Access
File
1 Citation (Scopus)

A randomized study of paclitaxel versus cyclophosphamide/methotrexate/- fluorouracil/prednisone in previously untreated patients with advanced breast cancer: Preliminary results

Bishop, J. F., Dewar, J., Toner, G., Tattersall, M. H., Olver, I., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., Walpole, E., Levi, J. & Stephenson, J., 1997, In : Seminars in Oncology. 24, 5 SUPPL. 17, p. S17-5-S17-9 5 p.

Research output: Contribution to journalArticle

9 Citations (Scopus)

A second Australian family with hemoglobin north shore (β134 val→glu)

Gurney, H., Baig, I., Gordon, S., Phadke, K., Kearsley, H., Fleming, P., Wyatt, K. & Hughes, W., 1987, In : Pathology. 19, 1, p. 62-63 2 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662

Diekstra, M. H. M., Klümpen, H. J., Lolkema, M. P. J. K., Yu, H., Kloth, J. S. L., Gelderblom, H., Van Schaik, R. H. N., Gurney, H., Swen, J. J., Huitema, A. D. R., Steeghs, N. & Mathijssen, R. H. J., 2014, In : Clinical Pharmacology and Therapeutics. 96, 1, p. 81-89 9 p.

Research output: Contribution to journalArticle

51 Citations (Scopus)

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 others, Bedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.

Research output: Contribution to journalArticle

65 Citations (Scopus)

Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., Lee, J. L., Vasiliev, A., Miller, W. H., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Bedke, J., Alekseev, B., Wang, J. & 8 others, Mariani, M., Robbins, P. B., Chudnovsky, A., Fowst, C., Hariharan, S., Huang, B., Di Pietro, A. & Choueiri, T. K., 21 Mar 2019, In : New England Journal of Medicine. 380, 12, p. 1103-1115 13 p.

Research output: Contribution to journalArticle

207 Citations (Scopus)

Bone metastases in hypernephroma. Frequency of scapular involvement

Gurney, H., Larcos, G., McKay, M., Kefford, R. & Langlands, A., 1989, In : Cancer. 64, 7, p. 1429-1431 3 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program

Parente, P., Ng, S., Parnis, F., Guminski, A. & Gurney, H., Dec 2017, In : Asia-Pacific Journal of Clinical Oncology. 13, 6, p. 391-399 9 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features

Shannon, C., Crombie, C., Brooks, A., Lau, H., Drummond, M. & Gurney, H., 2001, In : Annals of Oncology. 12, 7, p. 947-952 6 p.

Research output: Contribution to journalArticle

45 Citations (Scopus)

Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

Lee, C. K., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Reed, N., Gebski, V., Pujade-Lauraine, E., Lord, S., Simes, R. J. & Friedlander, M., 26 Jul 2011, In : British Journal of Cancer. 105, 3, p. 360-365 6 p.

Research output: Contribution to journalArticle

19 Citations (Scopus)

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M., 1 Jun 2018, In : BMJ Open. 8, 6, p. 1-6 6 p., e021064.

Research output: Contribution to journalArticle

Open Access
File
5 Downloads (Pure)

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S4, p. 66-66 1 p.

Research output: Contribution to journalMeeting abstract

Case series: silent malignant spinal cord compression (MSCC) secondary to spinal epidural metastases (SEM) in castrate-resistant prostate cancer (CRPC)

Park, J. J., Sabanathan, D., Lau, A. & Gurney, H., 2016, In : Asia-Pacific Journal of Clinical Oncology. 12, Suppl. S3, p. 38-38 1 p.

Research output: Contribution to journalMeeting abstract

Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer

Parente, P., Parnis, F. & Gurney, H., 2014, In : Asia-Pacific Journal of Clinical Oncology. 10, 3, p. 205-215 11 p.

Research output: Contribution to journalReview article

6 Citations (Scopus)

CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

Motzer, R. J., Escudier, B., Mcdermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L-A., Waxman, I. M., Sharma, P. & 1 others, CheckMate 025 Investigators, Dec 2015, In : BJU international. 116, S5, p. 17 1 p.

Research output: Contribution to journalMeeting abstract

12 Citations (Scopus)

CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

Sharma, P., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Xu, L. A., Waxman, I. M. & Motzer, R. J., Sep 2015, In : European Journal of Cancer. 51, Supplement 3, p. S708 1 p.

Research output: Contribution to journalMeeting abstract

CheckMate 025 randomized Phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma

Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Gurney, H., Donskov, F., Peltola, K., Wagstaff, J., Gauler, T. C., Ueda, T., Zhao, H., Waxman, I. M., Motzer, R. J. & 1 others, CheckMate 025 Investigators, 2017, In : European Urology. 72, 6, p. 962-971 10 p.

Research output: Contribution to journalArticle

97 Citations (Scopus)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

Lin, H. M., Castillo, L., Mahon, K. L., Chiam, K., Lee, B. Y., Nguyen, Q., Boyer, M. J., Stockler, M. R., Pavlakis, N., Marx, G., Mallesara, G., Gurney, H., Clark, S. J., Swarbrick, A., Daly, R. J. & Horvath, L. G., 13 May 2014, In : British Journal of Cancer. 110, 10, p. 2462-2471 10 p.

Research output: Contribution to journalArticle

78 Citations (Scopus)

Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer

Al-Mansouri, L. & Gurney, H., 1 Dec 2019, In : Asia-Pacific Journal of Clinical Oncology. 15, 6, p. 288-295 8 p.

Research output: Contribution to journalReview article

Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia

Parente, P., Gurney, H., Ng, S. & Bahre, M., 1 Sep 2015, In : Asia-Pacific Journal of Clinical Oncology. 11, 3, p. 199-207 9 p.

Research output: Contribution to journalReview article

3 Citations (Scopus)

Communicating risk in active surveillance of localised prostate cancer: A protocol for a qualitative study

Rapport, F., Hogden, A., Gurney, H., Gillatt, D., Bierbaum, M., Shih, P. & Churruca, K., 1 Oct 2017, In : BMJ Open. 7, 10, p. 1-7 7 p., e017372.

Research output: Contribution to journalArticle

Open Access
File
6 Downloads (Pure)

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: Updated analysis of a randomized trial

Grimison, P. S., Stockler, M. R., Thomson, D. B., Olver, I. N., Harvey, V. J., Gebski, V. J., Lewis, C. R., Levi, J. A., Boyer, M. J., Gurney, H., Craft, P., Boland, A. L., Simes, R. J. & Toner, G. C., 18 Aug 2010, In : Journal of the National Cancer Institute. 102, 16, p. 1253-1262 10 p.

Research output: Contribution to journalArticle

44 Citations (Scopus)

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumors: updated analysis of a randomized trial with 8 years follow-up

Grimison, P. S., Stockler, M. R., Thomson, D. B., Olver, I. N., Harvey, V. J., Gurney, H., Lewis, C. R., Gebski, V. J., Boland, A. L., Toner, G. C. & Australia New Zealand Germ Cell, 20 May 2009, In : Journal of Clinical Oncology. 27, 15, p. 5016-5016 2 p.

Research output: Contribution to journalMeeting abstract

Concomitant CYP2D6 inhibitor use and plasma metabolite levels in breast cancer patients treated with tamoxifen

Fox, P., Balakrishnar, B., Menzies, A., Liddle, C., Coulter, S., Provan, P., Gebski, V., Hui, R., Kefford, R., Wilcken, N., Balleine, R. & Gurney, H., 31 Jul 2012, In : Asia-Pacific Journal of Clinical Oncology. 8, Supplement 2, p. 52-52 1 p.

Research output: Contribution to journalMeeting abstract

Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

Al-Mansouri, L., Arasaratnam, M. & Gurney, H., 14 Jun 2019, In : European Journal of Hospital Pharmacy.

Research output: Contribution to journalArticle

Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer

Gurney, H., Harnett, P., Stuart-Harris, R. & Kefford, R., 1995, In : European Journal of Cancer. 31, 11, p. 1773-1777 5 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Cure in advanced renal cell cancer: Is it an achievable goal?

Sabanathan, D., Park, J. J., Marquez, M., Francisco, L., Byrne, N. & Gurney, H., 1 Dec 2017, In : Oncologist. 22, 12, p. 1470-1477 8 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen

Balakrishnar, B., Menzies, A. M., Ali, S. S., Yeap, S. H., Gao, B., Liddle, C., Coulter, S., Provan, P., Gebski, V., Hui, R., Kefford, R., Wilcken, N., Balleine, R. L. & Gurney, H., 20 May 2012, In : Journal of Clinical Oncology. 30, Supplement 15, p. 550-550 1 p.

Research output: Contribution to journalMeeting abstract

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy

Wong, M., Balleine, R. L., Collins, M., Liddle, C., Clarke, C. L. & Gurney, H., Jun 2004, In : Clinical Pharmacology and Therapeutics. 75, 6, p. 529-538 10 p.

Research output: Contribution to journalArticle

76 Citations (Scopus)

Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival

Patel, M. I., Beattie, K., Bang, A., Gurney, H. & Smith, D. P., Oct 2017, In : Cancer Medicine. 6, 10, p. 2188–2193 6 p.

Research output: Contribution to journalArticle

Open Access
File
12 Citations (Scopus)
2 Downloads (Pure)

Death of a clinical trial: A speculative inclusion criterion gone wrong [3]

Rosenthal, M. A., Woo, H., Gurney, H., Copeman, M. & Zingarelli, G., Dec 2007, In : Internal Medicine Journal. 37, 12, p. 838-839 2 p.

Research output: Contribution to journalLetter

Describing patterns of care in pancreatic cancer a population-based study: a population-based study

Burmeister, E. A., OʼConnell, D. L., Beesley, V. L., Goldstein, D., Gooden, H. M., Janda, M., Jordan, S. J., Merrett, N. D., Payne, M. E., Wyld, D. K., Neale, R. E. & Pancreatic Cancer Patterns of Care Study Group, Nov 2015, In : Pancreas. 44, 8, p. 1259-65 7 p.

Research output: Contribution to journalArticle

24 Citations (Scopus)

Developing a new framework for dose calculation

Gurney, H., 1 Apr 2006, In : Journal of Clinical Oncology. 24, 10, p. 1489-1490 2 p.

Research output: Contribution to journalEditorial

18 Citations (Scopus)